Metabolism in Psychiatry (MiP)
Head: Dr. Richard Musil
The Working Group on Metabolism in Psychiatry is dedicated to studying techniques to predict side effects of certain medications. In particular, we are interested in predicting weight gain associated with certain antidepressants, antipsychotics and mood stabilizers. Steady weight gain can result in overweight, which in turn increases the risk of developing a metabolic syndrome, diabetes and, ultimately, cardiovascular diseases. Furthermore, many patients discontinue their medications because of unpleasant side effects and, thus continue to have the symptoms of their mental illness, which can then also become chronic. The initial, preliminary results of our research show that eating behaviour before the start of drug treatment is a key predictor of weight gain within the first four weeks. Therefore, we conducted a pilot study to evaluate a psychoeducational ’Module on eating behaviour‘ that is tailored to patients with weight gain. Further, we are also interested in the association between psychotropic medication, inflammatory activities and the microbiome composition in relation to treatment response.
- Increase knowledge and raise awareness on metabolic disturbances in psychiatric patients
- Increase knowledge and raise awareness on weight gain during psychotropic treatment
- Increase knowledge on the association of inflammatory activation, metabolic disturbances and the microbiome composition in relation to treatment response
- Identify variables to predict weight gain and metabolic disturbances in patients treated with psychotropic medication
- Develop a prediciton tool for clinical routine care to identify patients at risk for weight gain/metabolic disturbances
- Develop specific weight gain prevention programs and programs accompanying the treatment
Focus: Prediction of metabolic changes associated with psychopharmacological treatment
- Metabolism in psychiatry - MiP II: Pilot study to evaluate a module of a psychotherapeutic prevention programme to change eating behaviour.
- Metabolism in psychiatry – MiP III
- Metabolism in psychiatry - MiP I
Barton, B. B., Simon, M. S., Glocker, C., Musil, R. (2020). Ein erheblicher Anteil von Psychopharmaka ist mit einer Gewichtzunahme assoziiert – was können wir tun? InFo Neurologie + Psychiatrie.
Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020). Update on weight gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf, 19(3):295–314. doi:10.1080/14740338.2020.1713091
Barton, B. B., Zagler, A., Engl, K., Rihs, L., & Musil, R. (2019). Prevalence of obesity, metabolic syndrome, diabetes and risk of cardiovascular disease in a psychiatric inpatient sample: results of the Metabolism in Psychiatry (MiP) Study. Eur Arch Psychiatry Clin Neurosci, 270(5):597-609. doi:10.1007/s00406-019-01043-8
Arteaga-Henríquez, G., Simon, M. S., Burger, B., Weidinger, E., Wijkhuijs, A., Arolt, V.,…Musil, R.,…et al. (2019). Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium. Front Psychiatry, 10:458. doi: 10.3389/fpsyt.2019.00458
Musil, R. (2015). Weight gain as a consequence of treatment with antipsychotics: What do we know and what can we do? Die Psychiatrie, 12(04): 262-268. doi_10.1055/s-0038-1669609
Musil, R., Obermeier, M., Russ, P., & Hamerle, M. (2015). Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf, 14(1):73–96. doi:10.1517/14740338.2015.974549
Musil, R., Schwarz, M. J., Riedel, M., Dehning, S., Cerovecki, A., Spellmann, I., et al. (2011). Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression — No influence of celecoxib treatment. Journal of Affective Disorders, 134(1-3): 217-225. doi: 10.1016/j.jad.2011.05.047
Musil, R., Spellmann, I., Riedel, M., Dehning, S., Douhet, A., Maino, K., et al. (2008). SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. J Psychiatr Res, 42(12):963–970. doi:10.1016/j.jpsychires.2007.11.003
- M.Sc. Barbara Barton (psychologist, psychotherapist, scientific research asisstant)
- M.Sc. Maria Simon (psychologist, scientific research assistant)
- Dr. med. Catherine Glocker (Specialist in Neurology and Psychiatry)
- Katharina Engl, Cand. med. dent.
- Anja Zagler, Cand. med. dent.
- Leonie Rihs, Cand. med.